This brand name is authorized in Nigeria.
The drug E-CAP contains one active pharmaceutical ingredient (API):
1
|
UNII
N3PA6559FT - ESOMEPRAZOLE
|
|
Esomeprazole is the S-isomer of omeprazole and reduces gastric acid secretion through a specific targeted mechanism of action. Esomeprazole is a weak base and is concentrated and converted to the active form in the highly acidic environment of the secretory canaliculi of the parietal cell, where it inhibits the enzyme H+ K+ -ATPase – the acid pump and inhibits both basal and stimulated acid secretion. |
|
This drug has been approved in Nigeria as follows:
| Identifier | Form | Presentation | Description | Approval |
|---|---|---|---|---|
| C4-0383 | Capsule | E-CAP CAPSULES CAP 20 mg 2 X 7 | E-CAP CAPSULES E-CAP ESOMEPRAZOLE 20MG POM CAPSULE 2 X 7 PROTON PUMP INHIBITOR PHARMAPLUS NIG. LTD., 7A, NIGER STREET, KANO, KANO STATE. BROOKES PHARMA (PRIVATE) LIMITED. 58-59, SECTOR NO. 15, KORANGI INDUSTRIAL AREA, KARACHI-74900, PAKISTAN GMP- RBC; LR- SATIS/FLAF; FEES- PAID; NP:NA 17/01/2017 C4-0383 | 30/01/2020 |
This drug has been assigned below unique identifiers within the countries it is being marketed:
| Country | Identification scheme | Identifier(s) |
|---|---|---|
| NG | Registered Drug Product Database | C4-0383 |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.